The National Comprehensive Cancer Network has moved into new headquarters in Plymouth Meeting, PA, near Philadelphia, from Fort Washington, PA. The new location will allow for greater hosting capacity for meetings, guests, and a growing staff.
NCCN moves global headquarters to Plymouth Meeting
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
THE CLINICAL CANCER LETTER
YOU MAY BE INTERESTED IN
I did not find the process of being suddenly without employment as refreshing as one might think. It did, however, provide a forced opportunity to engage in self-reflection, to critically analyze the situation around cancer, and to face the complex set of problems that cancer, and society, present to us.


In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models.


We are at a transformational period in oncology; the overall mortality from cancer is gradually declining in the United States.


Peritoneal metastases arise from gastrointestinal and gynecologic malignancies, leading to debilitating symptoms and poor prognoses. They remain one of the most challenging manifestations of advanced malignancies, often leading to significant morbidity and limited treatment options.


The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

